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Summary 
Soluble forms of ACE2 have recently been shown to inhibit SARS-CoV-2 infection. We 
report on an improved soluble ACE2, termed a “microbody” in which the ACE2 
ectodomain is fused to Fc domain 3 of the immunoglobulin heavy chain. The protein is 
smaller than previously described ACE2-Ig Fc fusion proteins and contains an H345A 
mutation in the ACE2 catalytic active site that inactivates the enzyme without reducing its 
affinity for the SARS-CoV-2 spike. The disulfide-bonded ACE2 microbody protein inhibits 
entry of SARS-CoV-2 spike protein pseudotyped virus and replication of live 
SARS-CoV-2 in vitro and in a mouse model. Its potency is 10-fold higher than soluble 
ACE2 and it can act after virus bound to the cell. The microbody inhibits the entry of β 
coronaviruses and virus with the variant D614G spike. The ACE2 microbody may be a 
valuable therapeutic for COVID-19 that is active against viral variants and future 
coronaviruses. 
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Introduction 
As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to 
spread worldwide, there is an urgent need for preventative vaccine and improved 
therapeutics for treatment of COVID-19. The development of therapeutic agents that 
block specific steps of the coronavirus replication cycle will be highly valuable both for 
treatment and prophylaxis. Coronavirus replication consists of attachment, uncoating, 
replication, translation, assembly and release, all of which are potential drug targets. 
Virus entry is particularly advantageous because as the first step in virus replication, it 
spares target cells from becoming infected and because drugs that block entry do not 
need to be cell permeable as the targets are externally exposed. In SARS-CoV-2 entry, 
the virus attaches to the target cell through the interaction of the spike glycoprotein with 
its receptor, the angiotensin-converting enzyme 2 (ACE2) (Li, 2015; Li et al., 2005; Li et 
al., 2003), a plasma membrane protein carboxypeptidase that degrades angiotensin II to 
angiotensin-(1–7) [Ang-(1–7)] a vasodilator that promotes sodium transport in the 
regulation of cardiac function and blood pressure (Kuba et al., 2010; Riordan, 2003; 
Tikellis and Thomas, 2012). ACE2 binding triggers spike protein-mediated fusion of the 
viral envelope with the cell plasma membrane or intracellular endosomal membranes. 
The spike protein is synthesized as a single polypeptide that is cleaved by the cellular 
protease furin into S1 and S2 subunits in the endoplasmic reticulum and then further 
processed by TMPRSS2 on target cells (Glowacka et al., 2011; Hoffmann et al., 2020; 
Matsuyama et al., 2010; Shulla et al., 2011). The S1 subunit contains the receptor 
binding domain (RBD) which binds to ACE2 while S2 mediates virus-cell fusion 
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(Belouzard et al., 2012; Fehr and Perlman, 2015; Heald-Sargent and Gallagher, 2012; Li 
et al., 2006; Shang et al., 2020). Cells that express ACE2 are potential targets of the 
virus. These include cells in the lungs, arteries, heart, kidney, and intestines (Harmer et 
al., 2002; Ksiazek et al., 2003; Leung et al., 2003).  
The use of soluble receptors to prevent virus entry by competitively binding to viral 
envelope glycoproteins was first explored for HIV-1 with soluble CD4. In early studies, a 
soluble form of CD4 deleted for the transmembrane and cytoplasmic domains was found 
to block virus entry in vitro (Daar et al., 1990; Haim et al., 2009; Orloff et al., 1993; 
Schenten et al., 1999; Sullivan et al., 1998). Fusion of the protein to an immunoglobulin 
Fc region, termed an “immunoadhesin”, increased the avidity for gp120 by dimerizing the 
protein and served to increase the half-life of the protein in vivo. An enhanced soluble 
CD4-Ig containing a peptide derived from the HIV-1 coreceptor CCR5 was found to 
potently block infection and to protect rhesus macaques from infection (Chiang et al., 
2012). The soluble receptor approach to blocking virus entry has been recently applied 
to SARS-CoV-2 through the use of recombinant human soluble ACE2 protein (hrsACE2) 
(Kuba et al., 2005; Monteil et al., 2020; Wysocki et al., 2010) or hrsACE2-IgG which 
encodes soluble ACE2 and the Fc region of the human immunoglobulin G (IgG) (Case et 
al., 2020; Lei et al., 2020; Qian and Hu, 2020) which were shown to inhibit of SARS-CoV 
and SARS-CoV-2 entry in a mouse model. In phase 1 and phase 2 clinical trials 
(Haschke et al., 2013; Khan et al., 2017), the protein showed partial antiviral activity but 
short half-live. Addition of the Fc region increased the half-life of the protein in vivo. A 
potential concern with the addition of the Ig Fc region is the possibility of enhancement, 
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similar to what occurs with antibody-dependent enhancement in which anti-spike protein 
antibody attaches to Fc receptors on immune cells, facilitating infection rather than 
preventing it (Eroshenko et al., 2020).  
We report, here on a soluble human ACE2 “microbody” in which the ACE2 
ectodomain is fused to domain 3 of immunoglobulin G heavy chain Fc region (IgG-CH3) 
(Maute et al., 2015). The IgG-CH3 Fc domain served to dimerize the protein, increasing 
its affinity for the SARS-CoV-2 S and decreased the molecular mass of the protein as 
compared to fusion with full-length Fc. The ACE2 microbody did not bind to cell surface 
Fc receptor, reducing any possibility of infection enhancement. Mutation of the active site 
H345 to alanine in the ACE2 microbody protein, a mutation that has been shown to 
inactivate ACE2 catalytic activity (Guy et al., 2005), did not decrease its affinity for the 
spike protein. The dimeric ACE2 microbody had about 10-fold higher antiviral activity than 
soluble ACE2, which was also a dimer, and high a higher affinity for virion binding. The 
ACE2 microbody blocked virus entry into ACE2.293T cells that over-expressed ACE2 as 
well as all of the cell lines tested. It was active against the D614G variant spike protein 
and against a panel of β coronavirus spike proteins and protected human ACE2 
transgenic mice against infection. 
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Results 
 
SARS-CoV-2 ∆19 spike protein was incorporated in pseudotyped virion and had 
higher infectivity.  
As a means to study SARS-CoV-2 entry, we developed an assay based on SARS-CoV-2 
spike protein pseudotyped lentiviral reporter viruses. The viruses package a lentiviral 
vector genome that encodes nanoluciferase and GFP separated by a P2A 
self-processing peptide, providing a convenient means to titer the virus, and the ability to 
use two different assays to measure infection. To pseudotype the virions, we constructed 
expression vectors for the full-length SARS-CoV-2 S and for a ∆19 variant, deleted for the 
carboxy-terminal 19 amino acids that removes a reported endoplasmic reticulum 
retention sequence that blocks transit of the spike protein to the cell surface (Giroglou et 
al., 2004) (Figure 1A). The vectors were constructed with or without a carboxy-terminal 
hemagglutinin (HA) epitope tag. Pseudotyped viruses were produced in 293T cells 
cotransfected with the dual nanoluciferase/GFP reporter lentiviral vector 
pLenti.GFP.NLuc, Gag/Pol expression vector pMDL and full-length spike protein, the 
∆19 spike protein, vesicular stomatitis virus G protein (VSV-G) expression vector or 
without an envelope glycoprotein expression vector. Immunoblot analysis showed that 
full-length and ∆19 spike proteins were expressed and processed into the cleaved S2 
protein (S1 is not visible as it lacks an epitope tag). Analysis of the virions showed that 
the ∆19 spike protein was packaged into virions at >20-fold higher levels than the 
full-length protein (Figure 1B). This difference was not the result of differences in virion 
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production as similar amounts of virion p24 capsid protein were present in the cell 
supernatant. Analysis of the transfected 293T cells by flow cytometry showed a minor 
increase in the amount of cell surface ∆19 spike protein as compared to full-length 
(Figure 1C) suggesting that deletion of the endoplasmic reticulum retention signal was 
not the primary cause of the increased virion packaging of the ∆19 spike protein and may 
result from an inhibitory effect of the spike protein cytoplasmic tail on virion incorporation. 
As a suitable target cell line, we established a clonal, stably transfected 293T cell line 
that expressed high levels of ACE2 (Figures 1D and S1). A comparison of the infectivity 
of the viruses on ACE2.293T cells showed that the ∆19 spike protein pseudotype was 
about 2.5-fold more infectious than the full-length spike protein pseudotype (Figure 1E). 
The HA-tag had no effect on infectivity and the nevirapine control demonstrated that the 
luciferase activity was the result of bona fide infection and not carried-over luciferase in 
the virus-containing supernatant.  
To determine the cell-type tropism of the pseudotyped virus, we tested several 
standard laboratory cell lines for susceptibility to infection to the ∆19 spike protein 
pseudotyped virus. The VSV-G pseudotype, which has very high infectivity on most 
cell-types was tested for comparison and virus lacking a glycoprotein was included to 
control for potential receptor-independent virus uptake. The results showed high 
infectivity of the ∆19 spike protein pseudotyped virus on ACE2.293T cells, intermediate 
infectivity on 293T, Vero, Vero E6, A549, ACE2.A549, CaCO2 and Huh7 and low 
infectivity on A549, CHME3 and BHK. (Figure 1F). Vero and Vero E6 are African Green 
Monkey cells and as such express TRIM5α which likely accounts for the slight decrease 
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in infectability of these cells by the VSV-G control pseudotype virus (Carthagena et al., 
2008; Nakayama and Shioda, 2010; Stremlau et al., 2004).  Flow cytometry analysis for 
ACE2 showed high level expression on ACE2.293T, intermediate level on ACE2.A549 
and a low to undetectable level on Vero, Vero E6, A549, CaCO2 and Huh7 (Figure S1). 
The absence of detectable ACE2 on these cell lines suggests either that virus can use 
very small amounts of the receptor for entry or that there is an alternative receptor. To 
test this hypothesis, we pre-treated the cells with a blocking anti-ACE2 antibody prior to 
infection. The antibody largely blocked infection of ACE2.293T but had no effect on 
infection of Vero and the other cell lines suggesting the presence of an alternative 
receptor (Figure 1G). 
 
An ACE2 microbody potently inhibits SARS-CoV-2 S-mediated virus entry. 
Soluble ACE2 and ACE2-Fc fusions have been shown to inhibit SARS-CoV-2 infection 
(Case et al., 2020; Kuba et al., 2010; Lei et al., 2020; Monteil et al., 2020; Qian and Hu, 
2020; Wysocki et al., 2010). To increase the effectiveness of soluble ACE2 and improve 
therapeutic potential, we generated an ACE2-“microbody” in which the ACE2 ectodomain 
was fused to a single IgG CH3 domain of the IgG Fc region (Figure 2A). This domain 
contains the disulfide bonding cysteine residues of the IgG Fc that are required to 
dimerize the protein, which would serve to increase the ACE2 microbody avidity for 
ACE2. To prevent potential unwanted effects of the protein on blood pressure due to the 
catalytic activity of ACE2, we mutated H345, one of the key active site histidine residues 
of ACE2, to alanine, a mutation that has been shown to block catalytic activity (Guy et 
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al., 2005). H345 lies underneath the spike protein interaction site so was predicted not to 
interfere with spike protein binding (Figure 2B). For comparison, we constructed vector 
encoding soluble ACE2 without the IgG CH3. The proteins were purified from transfected 
293T cells and purified to homogeneity by Ni-NTA agarose affinity chromatography 
followed by size exclusion chromatography (Figure S2). The oligomerization state of the 
proteins was analyzed by SDS-PAGE under nonreducing and reducing conditions. 
Under reducing conditions, the ACE2 and ACE2.H345A microbody proteins and soluble 
ACE2 ran at the 130 kDa and 120 kDa, consistent with their calculated molecular mass 
(Figures 2C and S2). Under nonreducing conditions, the ACE2 microbody and 
ACE2.H345A microbody proteins ran at 250 kDa, consistent with dimers while the 
soluble ACE2 ran as a monomer with a mass of 120 kDa (Figure 2C). Analysis of the 
proteins by size-exclusion chromatography coupled with multi-angle light scattering 
(SEC-MALS) under nondenaturing conditions showed all three proteins to have a 
molecular mass consistent with dimers (Figure 2D). The mass of the ACE2 and 
ACE2.H345A microbody proteins was 218 kDa and 230 kDa, respectively, while soluble 
ACE2 was 180 kDa. Taken together, the results suggest that the ACE2 microbody 
proteins are disulfide-bonded dimers while soluble ACE2 is a nondisulfide-bonded dimer.  
 
ACE2 microbody binds to SARS-CoV-2 pseudotyped virus.   
To compare the relative ability of the soluble ACE2 proteins to virions that display the 
spike protein, we established a virion pull-down assay. Ni-NTA beads were incubated 
with a serial dilution of the carboxy-terminal His-tagged soluble ACE2 proteins. Free spike 
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protein was removed and the beads were then incubated with a fixed amount of lentiviral 
pseudotyped virions. Free virions were removed and the bound virions were quantified by 
immunoblot analysis for virion p24 capsid protein. To confirm that virus binding to the 
beads was specific for the bead-bound ACE2, control virions lacking the spike were 
tested. The results showed that spike protein pseudotyped virions bound to the beads 
while virions that lacked the spike protein failed to bind, confirming that the binding was 
specific (Figure 3A). In addition, a high titer human serum from a recovered individual 
blocked binding of the virions to the bead-bound ACE2 microbody (Figure S5). Analysis 
of the soluble ACE2 and ACE2 microbody proteins that had bound to the beads showed 
that similar amounts of each proteins had bound (Figure 3B). Immunoblot analysis of 
virion binding to the bead-bound soluble ACE2 proteins showed that the wild-type and 
H345A microbody proteins both bound to virions more efficiently than soluble ACE2 
(Figure 3C) and that the ACE2.H345A microbody bound more virions than the wild-type 
microbody protein. This was unexpected as H345 does not lie in the interaction surface 
with the spike protein.   
 
ACE2 microbody blocks SARS-CoV-2 pseudotyped virus infection.  
To determine the relative antiviral activity of soluble ACE2 and the ACE2 microbody 
proteins, we tested their ability to block the infection SARS-CoV-2 ∆19 spike protein 
pseudotyped GFP/luciferase reporter virus. A fixed amount of pseudotyped reporter 
virus was incubated with the ACE2 proteins and then used to infect ACE2.293T cells. 
After 2 days, luciferase activity and the number of GFP+ cells in the infected cultures 
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were analyzed. For comparison, a high titered recovered patient serum with a 
neutralizing titer of 1:330 (figure S5) was also tested. The results showed that soluble 
ACE2 had moderate inhibitory activity with an EC50 of 1.24 µg/ml. The ACE2 microbody 
was significantly more potent, with an EC50 of 0.36 µg/ml and the ACE2.H345A 
microbody protein was somewhat more potent than the wild-type ACE2 microbody with 
an EC50 of 0.15 µg/ml (Figure 4A). Inhibition of infection by the soluble ACE2 proteins 
was comparable to recovered patient serum although it is not possible to directly 
compare the two inhibitors as the mass amount of anti-spike protein antibody in the serum 
is not known. To confirm the results, we analyzed the infected cells by flow cytometry to 
determine the number of GFP+ cells. The inhibition curves were similar to the luciferase 
curves, confirming that the ACE2 proteins had decreased the number of cells infected 
and did not simply reduce expression of the reporter protein (Figure 4B, top). 
Representative images of the GFP+ cells provide visual confirmation of the results 
(Figure 4B, below). The inhibitory activity of the soluble ACE2 proteins was specific for 
the SARS-CoV-2 spike protein as they did not inhibit VSV-G pseudotyped virus (Figure 
4C). The ACE2 microbody was somewhat more active when tested on untransfected 
293T that express low levels of ACE2 (Figure 4D).  
To determine the ability of the ACE2 microbody proteins to block the replication of 
live SARS-CoV-2, we used the replication-competent SARS-CoV-2, icSARS-CoV-2mNG 
that encodes an mNeonGreen reporter gene in ORF7 (Xie et al., 2020). Serially diluted 
ACE2 microbody proteins were incubated with the virus and the mixture was then used 
to infect ACE2.293T cells. The results showed that 1-0.125 µg of ACE2 microbody 
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protein blocked live virus replication (Figure 4E). Soluble ACE2 was less active; 1 µg of 
the protein had a 50% antiviral effect and the activity was lost with 0.5 µg. The antiviral 
activity of ACE2 proteins against live virus was similar to pseudotyped virus, except that 
in the live virus assay, the wild-type and H345A microbodies were of similar potency.   
In the experiments described above, the proteins were incubated with virus prior 
to infection. To determine whether they would be active at later time points, the ACE2 
proteins were tested in an “escape from inhibition” assay in which the soluble ACE2 and 
ACE2 microbody proteins were added to cells at the same time as virus or up to 6 hours 
post-infection. The results showed that addition of the microbody together with the virus 
(t0) blocked the infection by 80%. Addition of the microbody 30 minutes post-infection 
maintained most of the antiviral effect, and even 2 hours post-infection the inhibitor 
blocked 55% of the infection. At 4 hours post-infection, the ACE2 microbody retained its 
blocking activity at 10 µg/ml but was less active with decreasing amounts of inhibitor 
(Figure 5A). These results suggest that the ACE2 microbody is highly efficient at 
neutralizing the virus when present before the virus has had a chance to bind to the cell 
and that it maintains its ability to block infection when added together with the cells and 
even 2 hours after the virus has been exposed to cells, a time which most of the virus 
has not yet bound to the cell.  
To determine whether the ACE2 microbody could prevent virus entry once the 
virus bound to the cell, the virus was prebound by incubating it with cells for 2 hours at 
22°C, the unbound virus was removed and the ACE2 microbody was added at 
increasing time points. The results showed that removal of the unbound virus after 1 
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hour incubation resulted in less infection as compared to when the virus was incubated 
with the cells for 4 hours, indicating that only a fraction of the virus had bound to cells. 
However, virus that was bound could be blocked by the ACE2 microbody for another 30 
minutes post-binding (Figure 5B). The ability to block entry of the cell-bound virus 
suggests that virus binding results from a small number of spike molecules binding to 
ACE2. Over the next 30-60 minutes, additional spike protein:ACE2 interactions form, 
escaping the ability of the ACE2 microbody to block virus entry. The results demonstrate 
that the ACE2 microbody is a highly potent inhibitor of free virus and maintains its 
antiviral activity against virus newly-bound to the cell.   
 
ACE2 microbody blocks entry of virus with D614G mutant spike. A variant 
SARS-CoV-2 containing a D614G point mutation in the spike protein has been found to 
be circulating in the human population with increasing prevalence (Daniloski et al., 2020; 
Eaaswarkhanth et al., 2020; Korber et al., 2020). The D614G mutation was found to 
decrease shedding of the spike protein from the virus and to assume a fusion-ready 
conformation, resulting in increased infectivity and most likely contributing to its 
increasing prevalence (Daniloski et al., 2020; Ozono et al., 2020; Zhang et al., 2020). To 
determine the ability of the soluble ACE2 proteins to block entry of virus with the D614G 
spike protein, we introduced the mutation into the ∆19 spike protein expression vector 
and generated pseudotyped reporter viruses (Figure 6A). Analysis of the infectivity of the 
D614G and wild-type pseudotyped viruses on the panel of cell lines showed that the 
mutation increased the infectivity of virus 2-4 fold on 293T, ACE2.293T, Vero and VeroE6 
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cells, consistent with previous reports (Daniloski et al., 2020; Ozono et al., 2020; Zhang et 
al., 2020). Infectivity of the mutated virus was also increased in A549, ACE2.A549 
CaCO2 although the overall infectivity of these cells was low (Figure 6B). To determine 
the ability of the soluble ACE2 proteins to neutralize the virus with the variant spike 
protein, serial dilutions of the soluble ACE2 proteins were tested for their ability to block 
wild-type and D614G S pseudotyped virus. The results showed that soluble ACE2 had 
moderate antiviral activity against wild-type virus, while the wild-type and H345A 
microbody proteins were more potent (Figure 6C). The ACE2.H345A microbody was 
more active at low concentration than the wild-type protein. To test the relative binding 
affinities of the soluble ACE2 proteins for the wild-type and D614G spike proteins, we 
used an ACE2:virion binding assay in which the soluble ACE2 proteins were bound to 
nickel beads via their His-tag (Figure 6D). Different amounts of wild-type or D614G 
pseudotyped virions were then incubated with the beads and the amount of virions bound 
was quantified by immunoblot analysis. The results showed that the wild-type and H345A 
microbody proteins bound more efficiently than soluble ACE2 to the spike protein and that 
they bound well to both the wild-type and D614G spike protein-pseudotyped virions. 
 
ACE2 microbody neutralizes viruses with other β coronavirus spike proteins. To 
determine how well the ACE2 microbody would block the entry of other β coronaviruses, 
lentiviral virions pseudotyped by spike proteins from a panel of different lineage 2 β 
coronaviruses that use ACE2 for entry (Letko and Munster, 2020) (pcSARS-CoV, 
pcSARS-CoV2, pcWIV1, pcLYRa11, pcRs4231, pcRs4084 and pcSHC014) were 
Jo
ur
al 
Pr
e-p
roo
f
Tada et al. 
 
 
 16
generated. The pseudotypes were incubated with soluble ACE2 and the ACE2 
microbody proteins and their infectivity was then measured on ACE2.293T cells. The 
analysis showed that the ACE2 and H345A microbody proteins blocked all of the β 
coronavirus pseudotyped viruses while the antiviral activity of soluble ACE2 was 
significantly diminished in comparison (Figure 6E). The results demonstrate the broad 
activity of the ACE2 microbody.  
 
ACE2 microbody prevents infection in a SARS-CoV-2 mouse model. K18-hACE2 
transgenic mice express human ACE2 in epithelial airway cells (McCray et al., 2007). 
Infection of the mice with SARS-CoV2 by intranasal challenge results in virus replication 
that is first detected at day 2 in the lung and brain. The mice begin to lose weight at day 
2-4 and die from the inflammatory response at day 6-9 (Hassan et al., 2020; Winkler et 
al., 2020). To test the ability of the ACE2 microbody to prevent SARS-CoV-2 replication 
in vivo, we incubated live virus with the ACE2.H345 microbody protein, or buffer, and 
then administered the virus intranasally (i.n.). Mice infected with the buffer control-treated 
virus lost weight at day 2 while mice treated with the ACE2.H345A microbody showed no 
significant weight loss (Figure 7A). The control mice succumbed to the infection on day 
6 post-infection while mice treated with the ACE2.H345A microbody remained viable and 
healthy (Figure 7B). The results suggest that the microbody protein is able to prevent 
lethal SARS-CoV-2 disease in vivo.  
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Discussion 
We report the development of a soluble form of ACE2 in which the ectodomain of 
ACE2 is fused to a single domain of the IgG heavy chain Fc. The domain renders the 
protein smaller than those fused to the full-length Fc yet retains the cysteine residues 
required for dimerization and the ability to increase the in vivo half-life (Maute et al., 
2015). The microbody protein is a disulfide-bonded dimer in contrast to soluble ACE2 
lacking the Fc domain which is dimeric but not nondisulfide-bonded. Although both 
proteins are dimeric, the ACE2 microbody had about 10-fold more antiviral activity than 
soluble ACE2 and bound to virions with a >4-fold increased affinity. The ACE2.H345A 
microbody protected mice from intranasal SARS-CoV-2 infection in the K18-hACE2 
model.   
While high affinity neutralizing monoclonal antibodies against the virus are of 
great value in the treatment of COVID-19, soluble receptor proteins have advantageous 
features. The ACE2 microbody is fully of human origin so should be relatively 
non-immunogenic.  In addition, the requirement that the spike protein maintain its 
affinity for ACE2 should make it difficult for the virus to evolve escape mutants despite its 
relatively high mutation rate, as decreased binding to the soluble receptor proteins would 
decrease viral fitness. The microbody was fully active against virus with the D614G spike 
protein, a variant of increasing prevalence with increased infectivity in vitro (Figure 6B) 
and was highly active against ACE2-specific spike proteins from other β coronaviruses.  
It has been shown that a recombinant ACE2-Fc fusion caused a marked decrease 
in blood pressure in a mouse model (Liu et al., 2018). To prevent this unwanted effect in 
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the ACE2 microbody proteins, we introduced an H345A mutation into the protein. The 
mutation changes one of the histidine residues in the active site that is essential for 
ACE2 carboxypeptidase activity without impairing its antiviral activity against SARS 
CoV-2 or other β coronavirus spike proteins. In some experiments, the ACE2.H345A 
microbody appeared to be more active than the wild-type protein although the 
significance of this difference was unclear as the two proteins had similar activity in the 
live virus replication assay.  
Escape from inhibition studies provided insight into the kinetics of virus infection 
and the mechanism of inhibition by the soluble receptors. Pretreatment of virus with the 
ACE2 microbody potently neutralized the virus as did simultaneous addition of virus and 
microbody to cells. Furthermore, the protein retained its ability to prevent infection even 
when added to the culture at times after addition of virus, blocking infection by about 
50% when added 1 hour after virus addition. The ACE2 microbody was partially active 
even on virus that had already attached to the cell. When virus was pre-bound for 2 
hours, a time at which about 10% of the infectious virus had bound the cell, the ACE2 
microbody retained the ability to prevent infection of about 50% of the bound virus 
(Figure 5A). Taken together, the experiments suggest a series of events in which the 
virus binds to cells over a period of about 4 hours. During this time, the ACE2 microbody 
is highly efficient, neutralizing nearly all of the free virus. Once the virus binds to the cell, 
the ACE2 microbody retains its ability to block infection for about 30 minutes, suggesting 
that binding is initially mediated by a small number of spike proteins and that over 2 
hours, additional spike proteins are recruited to interact with target cell ACE2, a period 
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during which the ACE2 microbody remains able to block the viral fusion reaction. Once a 
sufficient number of spike protein:ACE2 interactions have formed, the virus escapes 
neutralization.   
As soluble ACE2 and the ACE2 microbody are both dimeric, it was surprising that 
the microbody had more antiviral activity. The ACE2 microbody protein also bound more 
efficiently to spike protein-pseudotyped virions. The reasons for this difference is not 
clear. It is possible that the disulfide bonds of the ACE2 microbody stabilize the dimer or 
that the individual monomers are positioned in a more favorable conformation to bind to 
the individual subunits of the spike protein trimer. Most of the experiments shown here 
used ACE2.293T cells that overexpress ACE2 as targets for infection. It is possible that 
the ACE2 microbody will have increased activity on cells that express ACE2 at 
physiological levels. Moreover, the ACE2 microbody protected untransfected 293T cells 
that do not express ACE2 and are infected through an alternative receptor.  
Recent reports have described similar soluble ACE2 proteins. Recently soluble 
ACE2-related inhibitor including rhACE2 was shown to partially block infection (Case et 
al., 2020; Lei et al., 2020; Monteil et al., 2020) although the proteins had a short half-life 
(Wysocki et al., 2010) (< 2 hours in mice), limiting their clinical usefulness. In contrast a 
dimeric rhesus ACE2-Fc fusion protein had a half-life in mice in plasma greater than 1 
week (Liu et al., 2018). The half-life of the ACE2 microbody in vivo has not yet been 
tested, but the protein retained antiviral activity for several days in tissue culture, 
significantly longer than longer than soluble ACE2 (Figure S3).  
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The phenomenon of antibody-dependent enhancement is caused by the 
interaction of the Fc domain of non-neutralizing antibody with the Fc receptor on cells 
which then serves to promote rather than inhibit virus neutralization. A similar 
phenomenon is possible with receptor-Fc fusion proteins by interaction with Fc receptor 
on cells. Because the ACE2 microbody contained only a single Fc domain, it was not 
expected to interact with Fc receptor. To test whether this was the case, we tested the 
ACE2 microbody in an enhancement assay using U937 cells which express Fc 
receptors. The ACE2 microbody protein did not detectably bind to cells that express the 
Fc γ receptor and the cells did not become infected, suggesting that this mechanism is 
not likely to play a role in vivo (Figure S4 and not shown). 
SARS-CoV-2 pseudotyped lentiviruses have been developed by several 
laboratories as tools for titering neutralizing antibodies and testing entry inhibitors 
(Crawford et al., 2020; Nie et al., 2020; Ou et al., 2020; Schmidt et al., 2020; Shang et 
al., 2020; Xia et al., 2020). The pseudotyped lentiviral vector system we developed here 
is highly effective.  The high infectivity of the viruses produced is due, in part, to 
codon-optimization of the spike protein and to the cytoplasmic tail truncation. The ∆19 
truncated spike protein was present at only slightly higher levels on the cell surface than 
the full-length protein, but was packaged 20-fold more efficiently. A possible explanation 
for the increased packaging efficiency is that the full-length cytoplasmic tail sterically 
hinders virion incorporation by conflicting with the underlying viral matrix protein. Also 
contributing to high viral titers, is the use of separate Gag/Pol packaging vector and 
lentiviral transfer vector as opposed to a lentiviral proviral DNA encoding Gag/Pol and 
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the reporter gene, which we have found resulted in much higher viral titer (not shown). 
The use of a dual nanoluciferase/GFP reporter in the system allows for measurement of 
infectious virus titer by flow cytometry and highly sensitivity nanoluciferase read-out. The 
results obtained using the lentiviral pseudotypes accurately reflect the results derived 
using live SARS-CoV-2.  In a study of sera from over 100 convalescent patients, the 
pseudotype assay results were closely correlated with titers determined in a live virus 
neutralization assay (Noval et al., 2020).  
A survey of a panel of cell lines for susceptibility to infection by the spike protein 
pseudotyped virus that included several of those in use for SARS-CoV-2 studies, none 
were anywhere near as infectable as the ACE2.293T cells and did not express 
detectable levels of ACE2. For example, Vero E6 and CaCO2 are highly susceptible to 
SARS-CoV-2 (Hoffmann et al., 2020) but were poorly infected by spike protein 
pseudotype virus (Figure 1F) and did not express detectable ACE2 (Figure S1) raising 
the question of how the cells support SARS-CoV-2 replication. The finding that 
pretreatment with a blocking anti-ACE2 antibody did not block their infection suggests 
that the cells are infected through an alternative receptor. While the postulated receptor 
supports only inefficient virus entry, it is sufficient to support robust virus replication. 
Recent reports have suggested alternative receptors (Cantuti-Castelvetri et al., 2020; 
Davanzo et al., 2020), although whether these are expressed on the cell lines tested is 
not clear.   
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A feature of soluble receptors is that because the virus spike protein needs to 
conserve its receptor binding affinity, they should maintain their ability to neutralize spike 
protein variants. SARS-CoV-2 S variants have been found to circulate in the human 
population and it is likely that others are yet to emerge, some of which may be less 
sensitive to neutralization by the therapeutic monoclonal antibodies currently under 
development. SARS-CoV-2 encoding the D614G spike protein has increased its 
frequency in the human population (Daniloski et al., 2020; Eaaswarkhanth et al., 2020; 
Korber et al., 2020). The D614G spike protein was found to be more resistant to 
shedding from the virion, adopting a conformation that favors ACE2-binding and lowers 
the energy barrier to cell fusion (Daniloski et al., 2020; Ozono et al., 2020; Zhang et al., 
2020). The ACE2 microbody maintained its ability to neutralize D614G spike 
protein-pseudotyped virus and was able to neutralize diverse β coronaviruses. The 
ACE2 microbody and similar soluble receptor proteins could be valuable tools able to 
neutralize coronaviruses that may be transferred to the human population in the future. 
Such soluble receptor proteins could serve as off-the-shelf reagents that could be rapidly 
deployed.  
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Main figure legends 
 
Figure 1. ∆19 SARS-CoV-2 pseudotyped lentiviral virion infection of ACE2.293T 
cells and ACE2 expressing cell lines (A) The domain structure of the SARS-CoV-2 
spike protein is diagrammed above. Yellow shading indicates the amino acids of the 
cytoplasmic domain retained following truncation of the 19 carboxy-terminal amino acids 
(∆19). Vectors encoding full-length (fl) codon-optimized SARS-CoV-2 spike protein or 
truncated ∆19 spike protein, with or without a carboxy-terminal HA-tag and the dual 
nanoluciferase/GFP lentiviral vector pLenti.NLuc.GFP used to generate pseudotyped 
lentiviral particles are diagrammed (below). NTD: N-Terminal domain, RBD: 
Receptor-binding domain, TM: Transmembrane domain IC: intracellular domain, RRE: 
Rev response element, LTR: Long terminal repeat. (B) SARS-CoV-2 spike proteins on 
pseudotyped lentiviral virions were analyzed. Transfected producer cell lysates (left) and 
supernatant virions (right) were analyzed on an immunoblot probed with anti-HA 
antibody. Cell lysate blots were probed with anti-GAPDH to normalize protein loading 
and virion blots were probed for HIV-1 p24 to normalize for virions. (C) 293T cells 
transfected with SARS-CoV-2 spike protein expression vectors were analyzed by flow 
cytometry to detect the protein at the plasma membrane. (D) HA-tagged ACE2 
expressed in control transfected 293T and clonal ACE2.293T cells were analyzed on an 
immunoblot probed with anti-HA antibody. (E) ACE2.293T cells were infected with virus 
pseudotyped by full-length or SARS-CoV-2 ∆19 spike proteins. Two days post-infection, 
infectivity was measured by luciferase assay. The reverse transcriptase inhibitor 
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nevirapine was added to one sample to control for free luciferase enzyme contamination 
of the virus stock. (F) A panel of cell lines were infected with VSV-G, SARS-CoV-2 ∆19 
spike protein or no envelope (no Env) pseudotyped lentivirus (MOI=0.2). Luciferase 
activity was measured two days post-infection. (G) ACE2.293T cells were treated with 
ACE2 antibody (1:20) for 30 minutes at room temperature and SARS-CoV-2 ∆19 virus 
was added on the cells. After 2 days of incubation, luciferase activity was measured. The 
data are represented as the mean of triplicates ± the standard deviation. Statistical 
significance was calculated with the student-t test. The experiment was done twice with 
similar results.  
 
Figure 2. Wild-type and H345A ACE2 microbody proteins are disulfide bonded 
dimers. (A) The domains of ACE2 are shown with the structures of the soluble ACE2 
(sACE2), ACE2 microbody and ACE2.H345A microbody proteins below. The soluble 
ACE2 proteins are deleted for the transmembrane (TM) and cytoplasmic domains. The 
ACE2 microbody proteins are fused to the human IgG CH3 domain each with a 
carboxy-terminal 8XHis-tag. IC: intracellular domain. (B) The diagram above shows the 
predicted dimeric structure of the ACE2 microbody protein. The 3D structure of the 
ACE2:spike protein complex was generated using Chimera software(Pettersen et al., 
2004) using published coordinates (Lan et al., 2020). The position of the conserved 
active site H345 in the ACE2 carboxypeptidase domain is shown lying underneath the 
ACE2 interaction site. (C) 293T cells were transfected with sACE2, ACE2 microbody and 
ACE2.H345A microbody expression vectors. The proteins were pulled-down on NTA 
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agarose beads and analyzed under reducing and nonreducing conditions on an 
immunoblot probed with anti-His-tag antibody. (D) The soluble ACE2 proteins were 
purified by metal chelate chromatography and size exclusion chromatography (SEC). 
The oligomerization state was determined by SEC multi-angle light scattering. The 
calculated molecular mass of each is shown. The experiment was done twice with similar 
results.   
 
Figure 3. ACE2 microbody proteins bind with high affinity to SARS-CoV-2 S 
pseudotyped virions. Nickel agarose beads were coated for 1 hour with 10 µg of 
soluble ACE2 proteins. Unbound protein was removed and SARS-CoV-2 ∆19 S 
pseudotyped virions or virions lacking spike protein were incubated with the beads. After 
1 hour, unbound virions were removed and the bound virions were analyzed on an 
immunoblot probed with antibody p24 antibody. (A) Input virions and bead-bound virions 
were analyzed on an immunoblot probed with anti-p24 antibody. (B) Soluble ACE2 
proteins bound to the nickel agarose beads were analyzed on an immunoblot probed 
with anti-His-tag antibody. (C) Soluble ACE2, wild-type ACE2 microbody and 
ACE2.H345A microbody proteins were serially diluted and bound to nickel agarose 
beads. The amount of bound virions was determined by immunoblot analysis with 
anti-p24 antibody. Quantification of the band intensities from the immunoblot is graphed 
below for soluble ACE2 (sACE2), wild-type ACE2 microbody (ACE2-mb) and 
ACE2.H345A microbody (H345A-mb). The experiment was done twice with similar 
results.   
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Figure 4. ACE2 and ACE2.H345A microbodies potently block virus entry and are 
active on different cell lines. (A) Serially diluted soluble ACE2, ACE2 and 
ACE2.H345A microbody proteins were incubated for 30 minutes with SARS-CoV-2 
∆19.S-pseudotyped virus and then added to ACE2.293T cells. Luciferase activity was 
measured 2 days post-infection. (B) The number of cells infected was determined by flow 
cytometry to quantify the GFP+ cells. The data are displayed as the percent GFP+ cells. 
Representative fluorescence microscopy images of the infected cells are shown below. 
Scale bar = 50 µm. (C) VSV-G pseudotyped lentiviral virions were incubated for 30 
minutes with 10 µg/ml of soluble ACE2 proteins and then added to ACE2.293T cells. 
Luciferase activity was measured 2 days post-infection. (D) ∆19 spike protein 
pseudotyped virus was incubated with serially diluted soluble ACE2 proteins for 30 
minutes and then added 293T cells. (E) Serially diluted soluble ACE2 proteins were 
incubated with mNeonGreen SARS-CoV-2 for 30 minutes. and then added to 
ACE2.293T cells. After 24 hours, the GFP+ cells were counted. Fluorescent microscopy 
images of representative fields from wells treated with 1 µg soluble ACE2 and ACE2 
microbody proteins are shown below. Scale bar = 2.1 mm. The data are displayed as the 
mean ± SD and significance is determined by student-t tests. The experiments in A-D 
were repeated 4 times and E was done twice.  
 
Figure 5. ACE2 microbody can act post-virus:cell binding. The kinetics of ACE2 
microbody inhibition were analyzed in an escape from inhibition escape assay. (A) The 
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experimental scheme is diagrammed above. SARS-CoV-2 ∆19.S-pseudotyped virus 
was added to ACE2.293T cells. Soluble ACE2 proteins were added immediately or at 
time points up to 6 hours later. Luciferase activity was measured 2 days post-infection. 
(B) As diagrammed above, virus was bound to target cells for 2 hours at 22°C and 
unbound virus was then removed. Soluble ACE2 proteins were added as in (A). The data 
are displayed as the mean ± SD and statistical significance determined by student-t 
tests. The experiment was done twice with similar results. 
 
Figure 6. ACE2 microbody blocks entry of the D614G variant spike protein 
pseudotyped virus infection and ACE2-using β coronavirus spike proteins. (A) The 
domain structure of the SARS-CoV-2 D614G ∆19 S expression vector is diagrammed 
above. Red star indicates the D614G mutation in the spike protein. (B) A panel of cell 
lines was infected with equivalent amounts (MOI=0.2) of wild-type and D614G ∆19 spike 
protein pseudotyped virus. (C) Serially diluted soluble ACE2 and ACE2 microbody 
proteins were mixed with D614G ∆19 spike protein pseudotyped virus and added to 
target cells. Luciferase activity was measured 2 days post-infection. The data are shown 
as the mean of triplicates ± SD. The statistical significance of the data was calculated 
with the student-t test. (D) Ni-NTA agarose beads were coated with serially diluted 
soluble ACE2 and ACE2 microbody proteins. Wild-type, ∆19 spike protein and no Env 
pseudotyped virions (28.2ng of p24) were added and allowed to bind. Unbound virions 
were removed after 30 minutes and the bound virions were detected by immunoblot 
analysis with anti-p24 antibody. The amount (ng) of beads-bound virus p24 was 
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calculated based on band intensities from the immunoblot and indicated in the bottom 
side. (E) Lentiviral virions pseudotyped by β coronavirus lineage 2 spike proteins were 
treated with serially diluted soluble ACE2 proteins and then used to infect 
ACE2.293Tcells. The identity of the virus from which the spike protein RBD is derived is 
indicated above each histogram. Luciferase activity was measured after 2 days. The 
data are displayed as the mean ± SD and significance is determined by student-t tests. 
The experiments in B and C were done three times and those in D and E were done 
twice. 
 
Figure 7. ACE2.H345A microbody protects K18-hACE2 transgenic mice from 
SARS-CoV-2 infection. ACE2.H345A microbody (7.5 µg) or control buffer was 
incubated for 30 minutes at room temperature with viral inoculum (1 X 103 PFU 
SARS-CoV-2). The virus was administered intranasally to K18h-ACE2 littermates (control 
n=9 and microbody n=10) and the mice were then monitored for weight loss (A) and 
survival (B). Data is pooled from two independent experiments. Weight loss was 
analyzed by a mixed-effects model. Survival was analyzed by a Logrank (Mantel-Cox) 
test. **** P<0.0001.
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STAR Methods 
Resource Availability 
Lead Contact 
Further information and requests for resources and reagents should be directed to and 
will be fulfilled by the Lead Contact, Nathaniel R. Landau 
(nathaniel.landau@med.nyu.edu). 
 
Materials Availability 
All unique DNA constructs, proteins and pseudotyped virus generated in this study are 
available from the Lead Contact upon request. 
 
Data and Code Availability 
Additional supplemental items are available from Mendeley Data at 
http://dx.doi.org/10.17632/hsbn73xpkt.1. 
 
Experimental Model and Subject Details 
Mouse care and in vivo SARS-CoV-2 neutralization. 
K18-hACE2 mice [B6.Cg-Tg(K18-ACE2)2Prlmn/J (McCray et al., 2007)] were purchased 
from The Jackson Laboratory and bred in-house. Mice of both sexes between 6 and 8 
weeks old were used for this study. SARS-CoV-2 stock was generated as previously 
described (Wei et al., 2020). Briefly, a SARS-CoV-2 P1 stock was generated by 
inoculating Vero E6 cells with SARS-CoV-2 isolate USA-WA1/2020 (BEI Resources, 
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NR-52281). The P1 stock was then used to inoculate Vero E6 cells at a MOI 0.01. After 
three days, the supernatant was harvested, clarified by centrifugation at 450 X g for 5 
minutes, filtered through a 0.45-micron filter and stored in aliquots at -80°C. Infectious 
titer of the virus determined by plaque assay on Vero.E6 cells (Wei et al., 2020). 
SARS-CoV-2 (2.0 X 104 PFU/ml) was mixed with ACE2 microbody (150 µg/ml) or buffer 
control and incubated for 30 minutes at room temperature. K18-hACE2 mice were 
anesthetized with 30% vol/vol isoflurane diluted in propylene glycol and administered 50 
µl of the mixture (1 X 103 PFU SARS-CoV-2 + 7.5 µg ACE2 microbody or 
volume-matched buffer control) intranasally. The mice were weighed and monitored daily 
for survival. Littermate controls were used for all experiments. Animal use and care was 
approved in agreement with the Yale Animal Resource Center and Institutional Animal 
Care and Use Committee (#2018-20198) according to the standards set by the Animal 
Welfare Act. 
 
Plasmids.  
The dual GFP/nanoluciferase lentiviral vector pLenti.GFP.NLuc was generated by 
overlap extension PCR. A DNA fragment encoding GFP was amplified with a forward 
primer containing a BamH-I site and a reverse primer encoding the P2A sequence. The 
nanoluciferase gene (NLuc) was amplified with a forward primer encoding the P2A motif 
and a reverse primer containing a 3’-Sal-I site. The amplicons were mixed and amplified 
with the external primers. The fused amplicon was cleaved with BamH-I and Sal-I and 
cloned into pLenti.CMV.GFP.puro (Addgene plasmid #17448, provided by Eric Campeau 
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and Paul Kaufman) (Campeau et al., 2009).   
The SARS-CoV-2 S expression vector pcCOV2.S was chemically synthesized as 
DNA fragments A and B encoding codon-optimized 5’ and 3’ halves, respectively, of the 
S gene of Wuhan-Hu-1/2019 SARS-CoV-2 isolate (Table S2 and S3). Fragment A was 
amplified with a forward primer containing a Kpn-I site and reverse primer containing an 
EcoR-I site. The amplicon was cleaved with Kpn-I and EcoR-I and cloned into pcDNA6 
(Invitrogen). Fragment B was amplified with a forward primer containing an EcoR-I site 
and reverse primer containing Mlu-I and Xho-I sites. The amplicon was cleaved with 
EcoR-I and Xho-I and cloned into pcDNA6. The cloned fragment A was then cleaved with 
Mlu-I and Xho-I and cloned into the Mlu-I and Xho-I sites in the fragment B-containing 
plasmid. To generate the SARS-CoV-2 S ∆19 expression vector pcCoV2.S.∆19, the 
codon-optimized S gene was amplified with a forward primer containing a Kpn-I site and 
reverse primer that deleted the 19 carboxy-terminal amino acids and contained an Xho-I 
site. The amplicon was cloned into the Kpn-I and Xho-I of pcDNA6. The D614G mutation 
in S was generated by overlap extension PCR of the ∆19 S gene using internal primers 
overlapping the sequence encoding D614G and cloned into pcDNA6. Beta coronavirus 
spike expression vectors (Letko and Munster, 2020) (pcSARS-CoV, pcSARS-CoV2, 
pcWIV1, pcLYRa11, pcRs4231, pcRs4084 and pcSHC014) were kindly provided by 
Michael Letko and Vincent Munster (NIH). 
ACE2 expressing lentiviral vector pLenti.ACE2 was generated by amplifying an 
ACE2 cDNA (Origene) with a forward primer containing an Xba-I site and reverse primer 
containing a Sal-I site. The amplicon was cleaved with Xba-I and Sal-I and cloned into 
Jo
urn
al 
Pr
e-p
ro
f
Tada et al. 
 
 
 33
pLenti.CMV.GFP.puro in place of GFP. The soluble ACE2 expression vector pcsACE2 
was generated by amplifying the extracellular domain of ACE2 with a forward primer 
containing a Kpn-I site and reverse primer encoding an in-frame 8XHis-tag and Xho-I 
site. The amplicon was then cloned into the Kpn-I and Xho-I sites of pcDNA6. The ACE2 
microbody expression vector pcACE2-microbody was generated by overlap extension 
PCR that fused the extracellular domain of ACE2 with human immunoglobulin G heavy 
chain Fc domain 3 using a forward primer containing a Kpn-I site and reverse primer 
containing an 8XHis-tag and Xho-1 site. The amplicon was cloned into the Kpn-I and 
Xho-I sites of pcDNA6. Expression vector pcACE2.H345A-microbody that expressed the 
ACE2.H345A microbody was generated by overlap extension PCR using primers that 
overlapped the mutation. Full-length cDNA sequence, primer sequences and amino acid 
sequences are shown in Tables S1, S2 and S3. 
 
Human sera.   
Control and recovered patient sera were collected from patients through the NYU 
Vaccine Center with written consent under I.R.B. approval (IRB 20-00595 and IRB 
18-02037) and were deidentified. Donor age and gender were not reported.  
 
Cells.  
Vero E6, CaCO2, A549, ACE2.A549, BHK, Huh7 293T, Vero and CHME3 cells were 
cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) and penicillin/streptomycin (P/S) at 37°C in 5% CO2. CaCO2 cells 
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were cultured in DMEM/10% FBS/1% nonessential amino acids. U937 cells were 
cultured in RPMI/10% FBS/ with P/S. ExpiCHO-S (Thermo Fisher Scientific) were 
cultured in ExpiCHO expression medium at 37 °C in 8% CO2. Cell line ACE2 expression 
levels were quantified by staining with anti-ACE2 antibody (NOVUS) and Alexa-fluor 
594-conjugated goat anti-mouse IgG (Biolegend) and pacific blue viability dye. Data 
were analyzed by flow cytometry with Flowjo software. ACE2.293T cells were 
established by lipofection of 293T cells with pLenti.ACE2-HA using lipofectamine 2000 
(Invitrogen). After 2 days, the cells were selected in 1 µg/ml puromycin and cloned at 
limiting dilution. Single cell clones were expanded and analyzed by flow cytometry and a 
single clone was chosen. A549 cells were transfected with pLenti.ACE2 using 
lipofectamine 2000. After two days, the cells were selected in medium containing 1 µg/ml 
puromycin and cloned at limiting dilution. Individual cell clones were screened by flow 
cytometry for high ACE2 expression and a single cell clone was expanded.  
 
Method Details 
 
SARS-CoV-2 lentiviral pseudotype assay.  
SARS-CoV-2 spike protein pseudotyped lentiviral stocks were produced by 
cotransfecting 293T cells (4 X 106) with pMDL, pLenti.GFP-NLuc, pcCoV2.S and 
pRSV.Rev at a mass ratio of 4:3:4:1 by calcium phosphate coprecipitation. Additional 
spike protein expression vectors were pcCoV2.S-∆19, pcCoV2.S-∆19.D614G or the β 
coronavirus RBD expression vectors. VSV-G pseudotyped lentivirus was similarly 
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produced substituting the spike protein vector for pcVSV-G. Virus lacking an envelope 
glycoprotein was produced by using pcDNA6 in place of pcCoV2.S. Virus-containing 
supernatant was harvested 2 days post-transfection, passed through a 0.45 µm filter and 
concentrated by ultracentrifugation over a 20% sucrose cushion at 30,000 RPM for 90 
minutes in an SW40.1 rotor in a Beckman Optima L-100K ultracentrifuge (Brea, CA). The 
pellet was resuspended to 1/10 the initial volume in DMEM/10% FBS and frozen in 
aliquots at -80°C. Virus stocks were titered on ACE2.293T by flow cytometry and reverse 
transcriptase activity using a real-time PCR assay (Vermeire et al., 2012).  
To test for infectabilty of cell lines, the cells in a 96 well tissue culture dish at 1 X 104 
cells/well were infected with pseudotyped lentivirus at MOI=0.2.  After 2 days, the 
culture medium was removed, 50 µls medium 50 and µls Nano-Glo luciferase substrate 
(Promega) was added and 70 µls was transferred to a microtiter plate which was read in 
an Envision 2103 microplate luminometer (PerkinElmer).  To test the inhibitory activity 
of soluble receptors and convalescent sera, 50 µl serially diluted soluble receptor or 
serum was incubated for 30 minutes at room temperature with reporter virus 
(corresponiing to approximately 25 X 106 cps luciferase activity) at a MOI of 0.2 in a 
volume of 100 µl. The mixture was added to ACE2.293T cells in a 96 well tissue culture 
dish containing 1 X 104 cells/well and then cultured for 2 days. Luciferase activity was 
measured by Nano-Glo assay and GFP+ cells were quantified by flow cytometry with 
pacific blue viability dye (Biolegend).  For antibody blocking, anti-ACE2 mAb (Novus) 
diluted 1:20 was added to the cells 30 minutes prior to infection.   
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Protein purification and molecular mass determination. 
293F cells (Thermo Fisher) at a density of 2.5 X 106 cells/ml were transfected with 
microbody expression vector plasmid DNA using polyethyleneimine (Polysciences, Inc) 
at a ratio of 1:3 plasmid:polyethyleneimine. The cells were then cultured at 30°C and at 
12 hours post-transfection, 10 mM sodium butyrate was added. After 4 days, the culture 
medium was collected, filtered and adjusted pH to 8.0. The medium was passed over a 5 
ml HiTrap Chelating column charged with nickel (GE healthcare), washed with 30 ml of 
buffer containing 20 mM Tris pH 8, 150 mM NaCl, 10 mM imidazole and the bound 
protein was eluted in buffer containing 250 mM imidazole. The eluate was concentrated 
to 1.0 ml and loaded onto a Superdex 200 size-exclusion column (GE healthcare) in 
running buffer containing 10 mM Tris pH 7.4, 150 mM NaCl. Protein containing fractions 
were pooled and concentrated. The purified proteins were analyzed on a 4-12% Bis-Tris 
SDS-PAGE stained with Coomassie blue. The yield of pure protein was 4 mg/liter of 
culture.   
The molecular masses of the purified protein complexes were determined by 
SEC/MALs. The proteins were injected onto a Superdex 200 10/300 GL gel-filtration 
chromatography column equilibrated in sample buffer connected to a Dawn Heleos II 
18-angle light-scattering detector (Wyatt Technology), a dynamic light-scattering detector 
(DynaPro Nanostar; Wyatt Technology) and an Optilab t-rEX refractive index detector 
(Wyatt Technology). The data were collected at 25°C at a flow rate of 0.5 ml/minute every 
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second. The molecular mass of each protein was determined by analysis with ASTRA 6 
software. 
 
Virion pull-down assay.  
293T cells were transfected by lipofection with 4.0 µg pcACE2-microbody. At 72 hours 
post-transduction, 0.5 ml of culture supernatant was incubated with nickel-nitrilotriacetic 
acid-agarose beads (QIAGEN). The beads were washed, and bound protein was eluted 
with Laemmle loading buffer. The proteins were analyzed on an immunoblot probed with 
mouse anti-6X His antibody (Invitrogen) and horseradish peroxidase (HRP)-conjugated 
goat anti-mouse IgG secondary antibody (Sigma-Aldrich). The proteins were visualized 
and quantified using luminescent substrate on an iBright CL1000 (Invitrogen) gel imager. 
Ratios were calculated as spike protein divided by P24 band intensities on an identical 
exposure of the blot. 
 
Immunoblot analysis.  
Transfected cells were lysed in buffer containing 50 mM HEPES, 150 mM KCl, 2 mM 
EDTA, 0.5% NP-40, and protease inhibitor cocktail. Protein concentration in the lysates 
was measured by bicinchoninic protein assay and the lysates (40 µg) were separated by 
SDS-PAGE. The proteins were transferred to polyvinylidene difluoride membranes and 
probed with anti-HA mAb (Covance), mouse anti-His mAb (Invitrogen) and anti-GAPDH 
mAb (Life Technologies) followed by goat anti-mouse HRP-conjugated second antibody 
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(Sigma). The blots were visualized using luminescent substrate (Millipore) on iBright 
CL1000. 
 
Binding assay.  
Soluble ACE2 proteins (10 µg) were mixed with 20 µl nickel beads for 1 hour at 4°C. 
Unbound protein was removed by washing the beads with PBS.  The beads were 
resuspended in PBS and mixed with 40 µl pseudotyped lentiviral virions. After 1 hour 
incubation at 4°C, the beads were washed with PBS and resuspended in reducing 
Laemmli loading buffer and heated to 90°C. The eluted proteins were separated by 
SDS-PAGE and analyzed on an immunoblot probed with anti-p24 antibody (AG3.0) 
followed by goat anti-mouse HRP-conjugated second antibody. 
 
Live SARS-CoV-2 neutralization assay.  
mNeonGreen SARS-CoV-2 (Xie et al., 2020) was obtained from the World Reference 
Center for Emerging Viruses and Arboviruses at the University of Texas Medical Branch. 
The virus was passaged once on Vero.E6 cells (ATCC CRL-1586), clarified by low-speed 
centrifugation, aliquoted, and stored at -80°C. The infectious virus titer was determined by 
plaque assay on Vero.E6 cells. Virus neutralization was determined as previously 
described (Xie et al., 2020). ACE2.293T cells were seeded in a 96-well plate (1 X 
104/well). The next day, mNeonGreen SARS-CoV-2 (MOI = 0.5) was mixed 1:1 with 
serially 2-fold diluted soluble ACE2 protein in DMEM/2% FBS and incubated for 1 hour at 
37°C. The virus:protein mixture was then added to the ACE2 cells and incubated for 24 
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hours at 37°C in 5% CO2. The cells were fixed with 4% paraformaldehyde, stained with 
DAPI and the green fluorescent cells were counted on a CellInsight CX5 Platform high 
content microscope (Thermo Fisher).  
 
Quantification and Statistical Analysis 
All experiments were performed in technical duplicates or triplicates and data were 
analyzed using GraphPad Prism (Version 7 7.0e). Statistical significance was 
determined by the two-tailed, unpaired t test. Significance was based on two-sided 
testing and attributed to p< 0.05. Confidence intervals are shown as the mean ± SD or 
SEM. (*P≤ 0.05, **P≤ 0.01, ***P≤0.001, ****P≤0.0001).  
 
 
Table S1. Primer sequence, Related to STAR Methods/Plasmids 
Table S2. cDNA sequence, Related to STAR Methods/Plasmids 
Table S3. Amino acid sequence, Related to STAR Methods/PlasmidsJo
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